Nippon Shinyaku, Boston Children’s to partner on rare disease research
Nippon Shinyaku (NS) Pharma will partner with Boston Children’s Hospital to study and develop treatments for rare diseases, like aromatic l-amino acid decarboxylase (AADC) deficiency. “Through our strategic alliance with Boston Children’s Hospital, the NS Group will continue to apply advanced medical technology in the field of rare…